Área Oncología

Grupo de investigación en neoplasias de línea mieloide

Mar Tormo Díaz

 

Grupo de investigación en Neoplasias de Línea Mieloide

Investigador colaborador

Blanca Navarro Cubells
Marisa Calabuig Muñoz
Montserrat Gómez Calafaz
Vicente Martín Guillem Primo
  • Estudios de nuevos factores pronósticos biológicos en leucemia aguda mieloblástica (en colaboración con el grupo cooperativo CETLAM).
  • Guías clínicas de diagnostico, pronóstico y tratamiento de los síndromes mielodisplásicos (en colaboración con el grupo cooperativo GESMD).
  • Estudio de factores que influyen en el riesgo de trombosis en síndromes mieloproliferativos Filadelfia-negativos.
  • Registro Español de Mielofibrosis.
Número total de publicaciones: 120. Factor de Impacto acumulado: 716.01
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2017 May 10. 1591-1597. FI: 24.008
Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
Calvo X, Arenillas L, Luño E, Senent L, Arnan M, Ramos F, Pedro C, Tormo M, Montoro J, Díez-Campelo M, Blanco ML, Arrizabalaga B, Xicoy B, Bonanad S, Jerez A, Nomdedeu M, Ferrer A, Sanz GF, Florensa L.
American journal of hematology. 2017 Mar 28. . FI: 5.275
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ, IRIS Investigators.
The New England journal of medicine. 2017 Mar 9. 917-927. FI: 72.40600000000001
Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin.
Rodríguez-Veiga R, Igual B, Montesinos P, Tormo M, Sayas MJ, Linares M, Fernández JM, Salvador A, Maceira-González A, Estornell J, Calabuig M, Pedreño M, Roig M, Sanz J, Sanz G, Carretero C, Boluda B, Martínez-Cuadrón D, Sanz MÁ, spanish PETHEMA group.
Annals of hematology. 2017 Apr 28. . FI: 3.083
Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS).
Martín I, Such E, Navarro B, Vicente A, López-Pavía M, Ibáñez M, Tormo M, Villamón E, Gómez-Seguí I, Luna I, Oltra S, Pedrola L, Sanz MA, Cervera J, Sanz G.
Leukemia & lymphoma. 2017 Jul. 1042-8194. FI: 2.755
Excess mortality in the myelodysplastic syndromes.
Nomdedeu M, Pereira A, Ramos F, Valcárcel D, Costa D, Arnan M, Calvo X, Pomares H, Luño E, Díaz-Campelo M, Collado R, de Paz R, Falantes JF, Pedro C, Marco J, Oirtzabal I, Sánchez-García J, Tormo M, Cedena MT, Nomdedeu B, Sanz G, Spanish MDS Group.
American journal of hematology. 2017 Feb. 149-154. FI: 5.275
The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia
Martínez-Trillos A, Pinyol M, Delgado J, Aymerich M, Rozman M, Baumann T, González-Díaz M, Hernández JM, Alcoceba M, Muntañola A, Terol MJ, Navarro B, Giné E, Jares P, Beà S, Navarro A, Colomer D, Nadeu F, Colado E, Payer AR, García-Cerecedo T, Puente XS, López-Otin C, Campo E, López-Guillermo A, Villamor N.
Leukemia & lymphoma. 2017 Nov 8. 1042-8194. FI: 2.755
Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia
Nadeu F, Clot G, Delgado J, Martín-García D, Baumann T, Salaverria I, Beà S, Pinyol M, Jares P, Navarro A, Suárez-Cisneros H, Aymerich M, Rozman M, Villamor N, Colomer D, González M, Alcoceba M, Terol MJ, Navarro B, Colado E, Payer ÁR, Puente XS, López-Otín C, López-Guillermo A, Enjuanes A, Campo E.
Leukemia. 2017 Sep 19. 0887-6924. FI: 11.702
Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group
Nomdedeu M, Pereira A, Calvo X, Colomer J, Sole F, Arias A, Gomez C, Luño E, Cervera J, Arnan M, Pomares H, Ramos F, Oiartzabal I, Espinet B, Pedro C, Arrizabalaga B, Blanco ML, Tormo M, Hernandez-Rivas JM, Díez-Campelo M, Ortega M, Valcárcel D, Cedena MT, Collado R, Grau J, Granada I, Sanz G, Campo E, Esteve J, Costa D; Spanish MDS Group.
Leukemia research. 2017 Oct 28. 0145-2126. FI: 2.501
Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia.
Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, Mercadal S, González-Campos J, Moreno MJ, Barba P, Cervera M, Barrios M, Novo A, Bernal T, Hernández-Rivas JM, Abella E, Amigo ML, Tormo M, Martino R, Lavilla E, Bergua J, Serrano A, García-Belmonte D, Guàrdia R, Grau J, Feliu E, PETHEMA Group, Spanish Society of Hematology.
Leukemia & lymphoma. 2017 May 30. 1-9. FI: 2.755
Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group.
Ramos F, Robledo C, Pereira A, Pedro C, Benito R, de Paz R, Del Rey M, Insunza A, Tormo M, Díez-Campelo M, Xicoy B, Salido E, Sánchez-Del-Real J, Arenillas L, Florensa L, Luño E, Del Cañizo C, Sanz GF, María Hernández-Rivas J, Spanish Group for Myelodysplastic Syndromes (GESMD).
American journal of hematology. 2017 Jun 13. . FI: 5.275
Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions
Puiggros A, Collado R, Calasanz MJ, Ortega M, Ruiz-Xivillé N, Rivas-Delgado A, Luño E, González T, Navarro B, García-Malo M, Valiente A, Hernández JÁ, Ardanaz MT, Piñan MÁ, Blanco ML, Hernández-Sánchez M, Batlle-López A, Salgado R, Salido M, Ferrer A, Abrisqueta P, Gimeno E, Abella E, Ferrá C, Terol MJ, Ortuño F, Costa D, Moreno C, Carbonell F, Bosch F, Delgado J, Espinet B.
Oncotarget. 2017 Apr 21. 1949-2553. FI: 5.168
Copy number profiling of adult relapsed B-cell precursor acute lymphoblastic leukemia reveals potential leukemia progression mechanisms.
Ribera J, Zamora L, Morgades M, Mallo M, Solanes N, Batlle M, Vives S, Granada I, Juncà J, Malinverni R, Genescà E, Guàrdia R, Mercadal S, Escoda L, Martinez-Lopez J, Tormo M, Esteve J, Pratcorona M, Martinez-Losada C, Solé F, Feliu E, Ribera JM, Spanish PETHEMA Group., Spanish Society of Hematology.
Genes, chromosomes & cancer. 2017 Jul 30. . FI: 3.696
Epstein-Barr virus DNA load kinetics analysis in allogeneic hematopoietic stem cell transplant recipients: Is it of any clinical usefulness?
Solano C1, Mateo EM2, Pérez A3, Talaya A4, Terol MJ3, Albert E2, Giménez E2, Vinuesa V2, Piñana JL3, Boluda JCH3, Navarro D5
Journal of clinical virology. 2017 Oct. 26-32. FI: 3.051
Epidemiologic and Clinical Characteristics of Coronavirus and Bocavirus Respiratory Infections after Allogeneic Stem Cell Transplantation: A Prospective Single-Center Study
Piñana JL Madrid S, Pérez A, Hernández-Boluda JC, Giménez E, Terol MJ, Calabuig M, Navarro D, Solano C
Biology of blood and marrow transplantation. 2017 Nov. . FI: 3.98
Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia
Hernández-Boluda JC, Correa JG, Alvarez-Larrán A, Ferrer-Marín F, Raya JM, Martínez-López J, Velez P, Pérez-Encinas M, Estrada N, García-Gutiérrez V, Fox ML, Luño E, Kerguelen A, Cuevas B, Durán MA, Ramírez MJ, Gómez-Casares M, Mata-Vázquez MI, Regadera A, Pereira A, Cervantes F; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)
British journal of haematology. 2017 Apr. . FI: 5.67
Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia
Alvarez-Larrán A1, Senín A1, Fernández-Rodríguez C2, Pereira A3, Arellano-Rodrigo E3, Gómez M4, Ferrer-Marin F5, Martínez-López J6, Camacho L2, Colomer D7, Angona A1, Navarro B4, Cervantes F8, Besses C1, Bellosillo B2, Hernández-Boluda JC4.
British journal of haematology. 2017 Sep. 764-771. FI: 5.67
Impact of cytomegalovirus DNAemia on overall and non-relapse mortality in allogeneic stem cell transplant recipients.
Solano C, Giménez E, Piñana JL, Albert E, Vinuesa V, Hernández-Boluda JC, Amat P, Navarro D
Transplant infectious disease : an official journal of the Transplantation Society.. 2017 May 4. . FI: 1.459
A time-to-event model for acute kidney injury after reduced intensity conditioning stem cell transplantation using a tacrolimus and sirolimus-based graft-versus-host disease prophylaxis.
Piñana JL, Perez-Pitarch A, Garcia-Cadenas I, Barba P, Hernandez-Boluda JC, Esquirol A, Fox ML, Terol MJ, Queraltó JM, Vima J, Valcarcel D, Ferriols-Lisart R, Sierra J, Solano C, Martino R
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2017 Apr 7. . FI: 3.98
A risk-adapted approach to treating respiratory syncytial virus and human parainfluenza virus in allogeneic stem cell transplantation recipients with oral ribavirin therapy: a pilot study.
Piñana JL, Hernández-Boluda JC, Calabuig M, Ballester I, Marín M, Madrid S, Teruel A, Terol MJ, Navarro D, Solano C
Transplant infectious disease : an official journal of the Transplantation Society.. 2017 May 19. . FI: 1.459
Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.
Casanova B, Jarque I, Gascón F, Hernández-Boluda JC, Pérez-Miralles F, de la Rubia J, Alcalá C, Sanz J, Mallada J, Cervelló A, Navarré A, Carcelén-Gadea M, Boscá I, Gil-Perotin S, Solano C, Sanz MA, Coret F
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.. 2017 Apr 10. . FI: 1.783
A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia
García-Gutiérrez V, Gómez-Casares MT, Puerta JM, Alonso-Domínguez JM, Osorio S, Hernández-Boluda JC, Collado R, Ramírez MJ, Ibáñez F, Martín ML, Rodríguez-Gambarte JD, Martínez-Laperche C, Gómez M, Fiallo DV, Redondo S, Rodríguez A, Ruiz-Nuño C, Steegmann JL, Jiménez-Velasco A; Spanish Group of Chronic Myeloid Leukemia (GELMC)
Plos One. 2017 Mar 9. e0173532. FI: 2.806
Feasibility of the AML profiler (Skyline™ Array) for patient risk stratification in a multicentre trial: a preliminary comparison with the conventional approach.
Nomdedéu JF, Puigdecanet E, Bussaglia E, Hernández JJ, Carricondo M, Estivill C, Martí-Tutusaus JM, Tormo M, Zamora L, Serrano E, Perea G, de Llano MPQ, García A, Sánchez-Ortega I, Ribera JM, Nonell L, Aventin A, Solé F, Brunet MS, Sierra J
Hematological oncology. 2017 Dec. 778-788. FI: 3.118
Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols.
Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, Brunet S, Bergua J, Tormo M, García-Boyero R, Sarrà J, Del Potro E, Grande C, Barba P, Bernal T, Amigo ML, Grau J, Cervera J, Feliu E, PETHEMA Group, Spanish Society of Hematology.
Leukemia & lymphoma. 2017 Jan. 145-152. FI: 2.755
The kinetics of torque teno virus plasma DNA load shortly after engraftment predicts the risk of high-level CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients
Albert E, Solano C, Giménez E, Focosi D, Pérez A, Macera L, Piñana JL, Boluda JCH, Maggi F, Navarro D
Bone marrow transplantation. 2017 Oct. . FI: 3.874
Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis
Hernández-Boluda JC, Pereira A, Correa JG, Alvarez-Larrán A, Ferrer-Marín F, Raya JM, Martínez-López J, Pérez-Encinas M, Estrada N, Velez P, Fox ML, García-Gutiérrez V, Payer A, Kerguelen A, Cuevas B, Durán MA, Ramírez MJ, Gómez-Casares MT, Mata-Vázquez MI, Mora E, Martínez-Valverde C, Gómez M, Cervantes F
Leukemia. 2017 Sep 22. . FI: 11.702
Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis
Hernández-Boluda JC, Correa JG, García-Delgado R, Martínez-López J, Alvarez-Larrán A, Fox ML, García-Gutiérrez V, Pérez-Encinas M, Ferrer-Marín F, Mata-Vázquez MI, Raya JM, Estrada N, García S, Kerguelen A, Durán MA, Albors M, Cervantes F
European journal of haematology. 2017 Apr. 407-414. FI: 2.653
Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real-world comparison
Tormo M, Pérez-Martínez A, Calabuig M, Hernández-Boluda JC, Amat P, Navarro D, Solano C
Mycoses. 2017 Nov 10. . FI: 6.183
Oxidative imbalance in low/intermediate-1-risk myelodysplastic syndrome patients: The influence of iron overload.
Ivars D, Orero MT, Javier K, Díaz-Vico L, García-Giménez JL, Mena S, Tormos C, Egea M, Pérez PL, Arrizabalaga B, Ruiz MÁ, Yagüe N, Tormo M, Sancho-Tello R, Gomes A, Algueró C, O'Connor JE, Sáez GT, Carbonell F, Collado R
Clinical biochemistry.. 2017 May 29. . FI: 2.382
When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients?
Solano C, Giménez E, Piñana JL, Hernández-Boluda JC, Amat P, Vinuesa V, Navarro D
Bone marrow transplantation.. 2017 Jun 5. . FI: 3.874
Lack of evidence for a reciprocal interaction between bacterial and cytomegalovirus infection in the allogeneic stem cell transplantation setting
Vinuesa V, Solano C, Giménez E, Piñana JL, Boluda JC, Amat P, Navarro D
Transplant international. 2016 Nov. 1196-1204. FI: 3.079
JAK2 inhibitors
Hernández Boluda JC, Gómez M, Pérez A
Medicina clínica. 2016 Jul 15. 70-5. FI: 1.267
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists
De Stefano V, Ruggeri M, Cervantes F, Alvarez-Larrán A, Iurlo A, Randi ML, Elli E, Finazzi MC, Finazzi G, Zetterberg E, Vianelli N, Gaidano G, Rossi E, Betti S, Nichele I, Cattaneo D, Palova M, Ellis MH, Cacciola R, Tieghi A, Hernandez-Boluda JC, Pungolino E, Specchia G, Rapezzi D, Forcina A, Musolino C, Carobbio A, Griesshammer M, Sant'Antonio E, Vannucchi AM, Barbui T
Leukemia. 2016 Oct. 2032-2038. FI: 11.702
GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study
Parody R, López-Corral L, Lopez-Godino O, Martinez C, Martino R, Solano C, Barba P, Caballero D, García-Cadenas I, Piñana JL, Marquez-Malaver FJ, Vazquez L, Esquirol A, Boluda JC, Sanchez-Guijo F, Pérez-Simon JA
Bone marrow transplantation. 2016 Nov. 1524-1526. FI: 3.874
Successful treatment of hepatitis C virus infection with sofosbuvir and simeprevir in the early phase of an allogeneic stem cell transplant.
Piñana JL, Serra MÁ, Hernández-Boluda JC, Navarro D, Calabuig M, Solano C
Transplant infectious disease : an official journal of the Transplantation Society.. 2016 Feb. 89-92. FI: 2.064
The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab.
Forero-Castro M, Robledo C, Lumbreras E, Benito R, Hernández-Sánchez JM, Hernández-Sánchez M, García JL, Corchete-Sánchez LA, Tormo M, Barba P, Menárguez J, Ribera J, Grande C, Escoda L, Olivier C, Carrillo E, García de Coca A, Ribera JM, Hernández-Rivas JM
British journal of haematology.. 2016 Feb. 428-38. FI: 4.711
Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera.
Gómez M, Guillem V, Pereira A, Ferrer-Marín F, Álvarez-Larrán A, Kerguelen A, Estrada N, Martínez-López J, Angona A, Amat P, Navarro B, Besses C, Hernández-Boluda JC
European journal of haematology. 2016 Mar. 285-90. FI: 2.653
Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.
Alvarez-Larrán A, Pérez-Encinas M, Ferrer-Marin F, Hernández-Boluda JC, Ramírez MJ, Martínez-López J, Magro E, Cruz Y, Mata MI, Aragües P, Fox ML, Cuevas B, Montesdeoca S, Hernández-Rivas JA, García-Gutiérrez V, Gómez-Casares MT, Steegmann JL, Durán MA, Gómez M, Kerguelen A, Bárez A, García MC, Boqué C, Raya JM, Martinez C, Albors M, Garcia F, Burgaleta C, Besses C
Haematologica. 2016 Sep 29. . FI: 7.702
Alleviating anemia and thrombocytopenia in myelofibrosis patients
Cervantes F, Correa JG, Hernandez-Boluda JC
Expert review of hematology. 2016 May. 489-96. FI: 2.246
Treatment patterns of adjuvant interferon-?2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study.
Espinosa E, Soriano V, Malvehy J, Berrocal A, Martínez de Prado P, Quindós M, Soria A, Márquez-Rodas I, Palacio I, Cerezuela P, López-Vivanco G, Alonso L, Samaniego E, Ballesteros A, Puértolas T, Díaz-Beveridge R, de la Cruz-Merino L, López Castro R, López López R, Stevinson K, Del Barrio P, Tornamira MV, Guillém V, Martín-Algarra S
Melanoma research.. 2016 Jun. 278-83. FI: 2.282
Association of RBP4 genetic variants with childhood obesity and cardiovascular risk factors
Codoñer-Franch P, Carrasco-Luna J, Allepuz P, Codoñer-Alejos A, Guillem V.
Pediatric diabetes. 2016 Dec. 576-583. FI: 4.267
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients
De Stefano V, Vannucchi AM, Ruggeri M, Cervantes F, Alvarez-Larrán A, Iurlo A, Randi ML, Pieri L, Rossi E, Guglielmelli P, Betti S, Elli E, Finazzi MC, Finazzi G, Zetterberg E, Vianelli N, Gaidano G, Nichele I, Cattaneo D, Palova M, Ellis MH, Cacciola E, Tieghi A, Hernandez-Boluda JC, Pungolino E, Specchia G, Rapezzi D, Forcina A, Musolino C, Carobbio A, Griesshammer M, Barbui T
Blood cancer journal. 2016 Nov. e493. FI: 6.126
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with CALR mutation.
Alvarez-Larrán A, Pereira A, Guglielmelli P, Hernández-Boluda JC, Arellano-Rodrigo E, Ferrer-Marín F, Samah A, Griesshammer M, Kerguelen A, Andreasson B, Burgaleta C, Schwarz J, García-Gutiérrez V, Ayala R, Barba P, Gómez-Casares MT, Paoli C, Drexler B, Zweegman S, McMullin MF, Samuelsson J, Harrison C, Cervantes F, Vannucchi AM, Besses C
Haematologica. 2016 May 12. . FI: 7.702
Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.
Ramos F, Robledo C, Izquierdo-García FM, Suárez-Vilela D, Benito R, Fuertes M, Insunza A, Barragán E, Del Rey M, de Morales JM, Tormo M, Salido E, Zamora L, Pedro C, Sánchez-Del-Real J, Díez-Campelo M, Del Cañizo C, Sanz GF, Hernández-Rivas JM, Spanish Group for Myelodysplastic Syndromes (GESMD)
Oncotarget. 2016 Apr 26. . FI: 6.359
Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes.
Arenillas L, Calvo X, Luño E, Senent L, Alonso E, Ramos F, Ardanaz MT, Pedro C, Tormo M, Marco V, Montoro J, Díez-Campelo M, Brunet S, Arrizabalaga B, Xicoy B, Andreu R, Bonanad S, Jerez A, Nomdedeu B, Ferrer A, Sanz GF, Florensa L
Journal of clinical oncology: official journal of the American Society of Clinical Oncology.. 2016 Jul 5. . FI: 20.982
Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method.
Besses C, Hernández-Boluda JC, Pérez Encinas M, Raya JM, Hernández-Rivas JM, Jiménez Velasco A, Martínez Lopez J, Vicente V, Burgaleta C, GEMFIN
Annals of hematology. 2016 Apr. 719-32. FI: 2.634
Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes.
Calvo X, Arenillas L, Luño E, Senent L, Arnan M, Ramos F, Ardanaz MT, Pedro C, Tormo M, Montoro J, Díez-Campelo M, Arrizabalaga B, Xicoy B, Bonanad S, Jerez A, Nomdedeu B, Ferrer A, Sanz GF, Florensa L
Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc.. 2016 Aug 26. . FI: 5.485
Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group.
Ribera JM, García O, Oriol A, Gil C, Montesinos P, Bernal T, González-Campos J, Lavilla E, Ribera J, Brunet S, Martínez MP, Tormo M, Genescà E, Barba P, Sarrà J, Monteserín MC, Soria B, Colorado M, Cladera A, García-Guiñón A, Calbacho M, Serrano A, Ortín X, Pedreño M, Amigo ML, Escoda L, Feliu E, PETHEMA Group, Spanish Society of Hematology
Leukemia research.. 2016 Feb. 44166. FI: 2.351
Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera.
Alvarez-Larrán A, Kerguelen A, Hernández-Boluda JC, Pérez-Encinas M, Ferrer-Marín F, Bárez A, Martínez-López J, Cuevas B, Mata MI, García-Gutiérrez V, Aragües P, Montesdeoca S, Burgaleta C, Caballero G, Hernández-Rivas JA, Durán MA, Gómez-Casares MT, Besses C, Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)
British journal of haematology. 2016 Mar. 786-93. FI: 5.67
Impact of anaemia on health-related quality of life and cardiac remodelling in patients with lower risk myelodysplastic syndromes. Results of GlobQoL study.
Ramos F, Pedro C, Tormo M, de Paz R, Font P, Luño E, Caballero M, Solano F, Almagro M, Xicoy B, Jiménez M
European journal of cancer care.. 2016 Jan 4. . FI: 1.564
Long-term results of prednisone treatment for the anemia of myelofibrosis.
Hernández-Boluda JC, Martínez-Trillos A, García-Gutiérrez V, Ferrer-Marín F, Xicoy B, Alvarez-Larrán A, Kerguelen A, Barba P, Gómez M, Herrera JC, Correa JG, Cervantes F
Leukemia & lymphoma. 2016 Jan. 120-4. FI: 2.891
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.
Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S, COMFORT Investigators
Haematologica.. 2015 Sep. 1139-45. FI: 5.814
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.
Sanz MA, Montesinos P, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte MR, Martínez L, Jacomo RH, Gutiérrez-Aguirre H, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Vellenga E, Holowiecka A, González-Huerta AJ, Fernández P, De la Serna J, Brunet S, De Lisa E, González-Campos J, Ribera JM, Krsnik I, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Rego EM, IC-APL and PETHEMA and HOVON Groups
Annals of hematology.. 2015 Aug. 1347-56. FI: 2.634
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.
Ramos F, Thépot S, Pleyer L, Maurillo L, Itzykson R, Bargay J, Stauder R, Venditti A, Seegers V, Martínez-Robles V, Burgstaller S, Récher C, Debén G, Gaidano G, Gardin C, Musto P, Greil R, Sánchez-Guijo F, Fenaux P, European ALMA Investigators
Leukemia research. 2015 Mar. 296-306. FI: 2.351
BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia.
Guillem V, Amat P, Collado M, Cervantes F, Alvarez-Larrán A, Martínez J, Tormo E, Eroles P, Solano C, Hernández-Boluda JC
Leukemia Research. 2015 Aug 28. . FI: 2.606
Complex Measurements May Be Required to Establish the Prognostic Impact of Immunophenotypic Markers in AML.
García-Dabrio MC, Hoyos M, Brunet S, Tormo M, Ribera JM, Esteve J, Gallardo D, Duarte RF, de Llano MP, Bargay J, Martí-Tutusaus JM, Heras I, Garcia A, Salamero O, Aventin A, Lecrevisse Q, Orfao A, Sierra J, Nomdedéu JF
American journal of clinical pathology. 2015 Sep. 484-92. FI: 2.514
Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results.
Cervantes F, Isola IM, Alvarez-Larrán A, Hernández-Boluda JC, Correa JG, Pereira A
Annals of hematology. 2015 Nov. 1791-6. FI: 2.634
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.
Bernal T, Martínez-Camblor P, Sánchez-García J, de Paz R, Luño E, Nomdedeu B, Ardanaz MT, Pedro C, Amigo ML, Xicoy B, del Cañizo C, Tormo M, Bargay J, Valcárcel D, Brunet S, Benlloch L, Sanz G, Spanish Group on Myelodysplastic Syndromes, PETHEMA Foundation, Spanish Society of Hematology
Leukemia.. 2015 Sep. 1875-81. FI: 10.431
Effects of metformin on mitochondrial function of leukocytes from polycystic ovary syndrome patients with insulin resistance.
Victor VM, Rovira-Llopis S, Bañuls C, Diaz-Morales N, Castelló R, Falcón R, Gómez M, Rocha M, Hernández-Mijares A
European journal of endocrinology. 2015 Nov. 683-91. FI: 4.069
Fluorescence in situ hybridization analysis does not increase detection rate for trisomy 8 in chronic myelomonocytic leukemia.
Saumell S, Florensa L, Rodríguez-Rivera M, Pedro C, Hernández-Rivas JM, Lumbreras E, Abáigar M, Collado R, Ivars D, Carbonell F, Marugán I, Tormo M, Botia M, Piñan MÁ, Ancín I, González T, Varela ND, Grau J, Granada I, Ruiz N, Martín ML, Fernández-Guijarro M, Duarte JJ, Calasanz MJ, Larrayoz MJ, Solé F
Leukemia & lymphoma. 2015 Jan. 242-3. FI: 2.891
Metformin modulates human leukocyte/endothelial cell interactions and proinflammatory cytokines in polycystic ovary syndrome patients.
Victor VM, Rovira-Llopis S, Bañuls C, Diaz-Morales N, Lopez-Domenech S, Escribano-López I, Rios-Navarro C, Alvarez A, Gomez M, Rocha M, Hernandez-Mijares A
Atherosclerosis. 2015 Jul 10. 167-173. FI: 3.994
Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score.
Falantes J, Delgado RG, Calderón-Cabrera C, Márquez-Malaver FJ, Valcarcel D, de Miguel D, Bailén A, Bargay J, Bernal T, González-Porras JR, Tormo M, Ramos F, Andreu R, Xicoy B, Nomdedeu B, Brunet S, Sánchez J, Jurado AF, Bonanad S, Pérez-Simón JA, Sanz G, Spanish Group of Myelodysplastic Syndromes (GESMD)
Leukemia research. 2015 Jan. 52-7. FI: 2.351
Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia.
Hernández-Boluda JC, Arellano-Rodrigo E, Cervantes F, Alvarez-Larrán A, Gómez M, Barba P, Mata MI, González-Porras JR, Ferrer-Marín F, García-Gutiérrez V, Magro E, Moreno M, Kerguelen A, Pérez-Encinas M, Estrada N, Ayala R, Besses C, Pereira A, Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)
Annals of hematology. 2015 Jun. 911-8. FI: 2.634
Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols.
Ribera J, Morgades M, Zamora L, Montesinos P, Gómez-Seguí I, Pratcorona M, Sarrà J, Guàrdia R, Nomdedeu J, Tormo M, Martínez-Lopez J, Hernández-Rivas JM, González-Campos J, Barba P, Escoda L, Genescà E, Solé F, Millá F, Feliu E, Ribera JM, Spanish PETHEMA Group and the Spanish Society of Hematology
Cancer cytopathology.. 2015 Nov 1. 3809-17. FI: 4.889
Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia.
Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G
European journal of haematology.. 2015 Sep 5. . FI: 2.066
Target hematologic values in the management of essential thrombocythemia and polycythemia vera.
Hernández-Boluda JC, Gómez M
European journal of haematology. 2015 Jan. 42678. FI: 2.066
The CHADS2 Score to Predict Stroke Risk in the Absence of Atrial Fibrillation in Hypertensive Patients Aged 65 Years or Older.
Morillas P, Pallarés V, Fácila L, Llisterri JL, Sebastián ME, Gómez M, Castilla E, Camarasa R, Sandin M, García-Honrubia A, FAPRES registry investigators
Revista espanola de cardiologia (English ed.). 2015 Jun. 485-91
The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
Díaz-Beyá M, Brunet S, Nomdedéu J, Cordeiro A, Tormo M, Escoda L, Ribera JM, Arnan M, Heras I, Gallardo D, Bargay J, Queipo de Llano MP, Salamero O, Martí JM, Sampol A, Pedro C, Hoyos M, Pratcorona M, Castellano JJ, Nomdedeu M, Risueño RM, Sierra J, Monzó M, Navarro A, Esteve J
Blood cancer journal. 2015 Oct 2. e352. FI: 3.467
The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.
Díaz-Beyá M, Brunet S, Nomdedéu J, Pratcorona M, Cordeiro A, Gallardo D, Escoda L, Tormo M, Heras I, Ribera JM, Duarte R, de Llano MP, Bargay J, Sampol A, Nomdedeu M, Risueño RM, Hoyos M, Sierra J, Monzo M, Navarro A, Esteve J, Cooperative AML group CETLAM
Oncotarget. 2015 Oct 13. 31613-27. FI: 6.359
Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study.
Valcárcel D, Sanz G, Ortega M, Nomdedeu B, Luño E, Diez-Campelo M, Ardanaz MT, Pedro C, Montoro J, Collado R, Andreu R, Marco V, Cedena MT, de Paz R, Tormo M, Xicoy B, Ramos F, Bargay J, Gonzalez B, Brunet S, Muñoz JA, Gomez V, Bailén A, Sanchez J, Merchán B, Del Cañizo C, Vallespí T, Grupo Español de Síndromes Mielodisplásicos (GESMD)
The Lancet. Haematology.. 2015 Jun. e260-6
Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis.
Rojas SM, Díez-Campelo M, Luño E, Cabrero M, Pedro C, Calabuig M, Nomdedeu B, Cedena T, Arrizabalaga B, García M, Cerveró C, Collado R, Azaceta G, Ardanaz MT, Muñoz JA, Xicoy B, Rodríguez MJ, Bargay J, Morell MJ, Simiele A, Del Cañizo C
Leukemia research. 2014 Mar. 304-9. FI: 2.692
MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia.
Díaz-Beyá M, Brunet S, Nomdedéu J, Tejero R, Díaz T, Pratcorona M, Tormo M, Ribera JM, Escoda L, Duarte R, Gallardo D, Heras I, Queipo de Llano MP, Bargay J, Monzo M, Sierra J, Navarro A, Esteve J
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2014 Apr. 804-12. FI: 9.379
The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.
Hernández-Boluda JC, Pereira A, Gómez M, Boqué C, Ferrer-Marín F, Raya JM, García-Gutiérrez V, Kerguelen A, Xicoy B, Barba P, Martínez J, Luño E, Alvarez-Larrán A, Martínez-López J, Arbelo E, Besses C, Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)
Haematologica. 2014 Apr. e55-7. FI: 5.868
Indirect and non-medical economic burden, quality-of-life, and disabilities of the myelofibrosis disease in Spain.
Gimenez E, Besses C, Boque C, Velez P, Kerguelen A, Cervantes F, Ferrer-Marin F, Perez-Encinas M, Rodriguez M, Gonzalez JD, Calzada R, Hernandez-Boluda JC
Journal of medical economics. 2014 Jun. 435-41
Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
Alvarez-Larrán A, Martínez-Avilés L, Hernández-Boluda JC, Ferrer-Marín F, Antelo ML, Burgaleta C, Mata MI, Xicoy B, Martínez-Trillos A, Gómez-Casares MT, Durán MA, Marcote B, Ancochea A, Senín A, Angona A, Gómez M, Vicente V, Cervantes F, Bellosillo B, Besses C
Annals of hematology. 2014 Dec. 2037-43. FI: 2.396
Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome.
Martínez-Trillos A, Pinyol M, Navarro A, Aymerich M, Jares P, Juan M, Rozman M, Colomer D, Delgado J, Giné E, González-Díaz M, Hernández-Rivas JM, Colado E, Rayón C, Payer AR, Terol MJ, Navarro B, Quesada V, Puente XS, Rozman C, López-Otín C, Campo E, López-Guillermo A, Villamor N
Blood. 2014 Jun 12. 3790-6. FI: 9.775
Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia.
García-Delgado R, de Miguel D, Bailén A, González JR, Bargay J, Falantes JF, Andreu R, Ramos F, Tormo M, Brunet S, Figueredo A, Casaño J, Medina A, Badiella L, Jurado AF, Sanz G
Leukemia research. 2014 Jul. 744-50. FI: 2.692
The commitment and evaluation of the quality management plan by professionals from accredited stem cell transplant centers in Spain.
Jiménez MJ, Ferra C, García O, de Arriba F, Jiménez S, Insunza A, Calabuig M, Mantecon A, Sánchez J, Torres M, Balsalobre P, Linio J, Jiménez A, Feliu E, Ribera JM
Bone marrow transplantation. 2014 Jul. 990-2. FI: 3.466
Treatment of high-risk philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA
Ribera JM, Oriol A, Morgades M, Montesinos P, Sarrà J, González-Campos J, Brunet S, Tormo M, Fernández-Abellán P, Guàrdia R, Bernal MT, Esteve J, Barba P, Moreno MJ, Bermúdez A, Cladera A, Escoda L, García-Boyero R, Del Potro E, Bergua J, Amigo ML, Grande C, Rabuñal MJ, Hernández-Rivas JM, Feliu E
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 May 20. 1595-604. FI: 17.879
Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols.
Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, González-Campos J, Fernández-Abellán P, Tormo M, Bethencourt C, Brunet S, Hernández-Rivas JM, Moreno MJ, Sarrà J, Del Potro E, Barba P, Bernal T, Grande C, Grau J, Cervera J, Feliu E, PETHEMA Group, Spanish Society of Hematology
Cancer. 2014 Dec 15. 3958-64. FI: 4.901
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernández-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, O'Hare T
Cancer cell. 2014 Sep 8. 428-42. FI: 23.893
Reply to "The association of red blood cell distribution width and morbid obesity" by Aydin et al.
Vayá A, Alis R, Hernandez-Mijares A, Solá E, Cámara R, Rivera L, Romagnoli M, Laiz B
Clinical biochemistry. 2014 Sep. 1350. FI: 2.229
Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
Sánchez-García J, Del Cañizo C, Lorenzo I, Nomdedeu B, Luño E, de Paz R, Xicoy B, Valcárcel D, Brunet S, Marco-Betes V, García-Pintos M, Osorio S, Tormo M, Bailén A, Cerveró C, Ramos F, Diez-Campelo M, Such E, Arrizabalaga B, Azaceta G, Bargay J, Arilla MJ, Falantes J, Serrano-López J, Sanz GF, Spanish Group on Myelodysplastic Syndromes (GES MD)
British journal of haematology. 2014 Jul. 189-201. FI: 4.959
Results of allogeneic stem cell transplantation in the Spanish MDS registry: Prognostic factors for low risk patients.
Díez Campelo M, Sánchez-Barba M, de Soria VG, Martino R, Sanz G, Insunza A, Bernal T, Duarte R, Amigo ML, Xicoy B, Tormo M, Iniesta F, Bailén A, Benlloch L, Córdoba I, López-Villar O, Del Cañizo MC, Spanish Registry of MDS
Leukemia research. 2014 Oct. 1199-206. FI: 2.692
JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: Clinical usefulness for predicting myelofibrotic transformation and thrombotic events.
Alvarez-Larrán A, Bellosillo B, Pereira A, Kerguelen A, Carlos Hernández-Boluda J, Martínez-Avilés L, Fernández-Rodríguez C, Gómez M, Lombardía L, Angona A, Ancochea A, Senín A, Longarón R, Navarro B, Collado M, Besses C
American journal of hematology. 2014 May. 517-23. FI: 3.798
Vascular endothelial growth factor A (VEGFA) gene polymorphisms have an impact on survival in a subgroup of indolent patients with chronic lymphocytic leukemia.
Lozano-Santos C, Martinez-Velasquez J, Fernandez-Cuevas B, Polo N, Navarro B, Millan I, Garcia JM, Collado R, Sanchez-Godoy P, Carbonell F, Garcia-Vela JA, Garcia-Marco JA, Gomez-Lozano N
PloS one. 2014. e101063. FI: 3.534
Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome.
Muñiz C, Martín-Martín L, López A, Sánchez-González B, Salar A, Almeida J, Sancho JM, Ribera JM, Heras C, Peñalver FJ, Gómez M, González-Barca E, Alonso N, Navarro B, Olave T, Sala F, Conde E, Márquez JA, Cabezudo E, Cladera A, García-Malo M, Caballero MD, Orfao A, Spanish Group for the Study of Central Nervous System Disease in Non-Hodgkin Lymphoma
Blood. 2014 Mar 20. 1864-9. FI: 9.775
Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma.
Bellas C, García D, Vicente Y, Kilany L, Abraira V, Navarro B, Provencio M, Martín P
PloS one. 2014. e98169. FI: 3.534
A polymorphism in the TYMP gene is associated with the outcome of HLA-identical sibling allogeneic stem cell transplantation.
Guillem V, Hernández-Boluda JC, Gallardo D, Buño I, Bosch A, Martínez-Laperche C, de la Cámara R, Brunet S, Martin C, Nieto JB, Martínez C, Pérez A, Montoro J, Garcia-Noblejas A, Solano C, Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH)
American journal of hematology. 2013 Oct. 883-9. FI: 3.477
Acral localized acquired cutis laxa.
Martí N, Monteagudo C, Revert A, Reig I, Gámez L, Jordá E
International journal of dermatology. 2013 Aug. 983-6. FI: 1.342
Surgical treatment of gastrointestinal stromal tumours. Analysis of our experience.
Martí Obiol R, Garcés Albir M, López Mozos F, Ortega Serrano J
Cirugía española. 2013 Jan. 38-43. FI: 0.871
False positive rate of an arrayCGH platform for single-cell preimplantation genetic screening and subsequent clinical application on day-3.
Mir P, Rodrigo L, Mercader A, Buendía P, Mateu E, Milán-Sánchez M, Peinado V, Pellicer A, Remohí J, Simón C, Rubio C
Journal of assisted reproduction and genetics. 2013 Jan. 143-9. FI: 1.823
Focal DNA copy number changes in neuroblastoma target MYCN regulated genes.
Kumps C, Fieuw A, Mestdagh P, Menten B, Lefever S, Pattyn F, De Brouwer S, Sante T, Schulte JH, Schramm A, Van Roy N, Van Maerken T, Noguera R, Combaret V, Devalck C, Westermann F, Laureys G, Eggert A, Vandesompele J, De Preter K, Speleman F
PloS one. 2013. e52321. FI: 3.73
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.
Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, Rossi D, Cavalli M, Wijermans P, Ria R, Offidani M, Lahuerta JJ, Liberati AM, Mina R, Callea V, Schaafsma M, Cerrato C, Marasca R, Franceschini L, Evangelista A, Teruel AI, van der Holt B, Montefusco V, Ciccone G, Boccadoro M, Miguel JS, Sonneveld P, Palumbo A
Haematologica. 2013 Jun. 980-7. FI: 5.935
Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab).
Ribera JM, García O, Grande C, Esteve J, Oriol A, Bergua J, González-Campos J, Vall-Llovera F, Tormo M, Hernández-Rivas JM, García D, Brunet S, Alonso N, Barba P, Miralles P, Llorente A, Montesinos P, Moreno MJ, Hernández-Rivas JÁ, Bernal T
Cancer. 2013 May 1. 1660-8. FI: 5.201
Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.
Pratcorona M, Brunet S, Nomdedéu J, Ribera JM, Tormo M, Duarte R, Escoda L, Guàrdia R, Queipo de Llano MP, Salamero O, Bargay J, Pedro C, Martí JM, Torrebadell M, Díaz-Beyá M, Camós M, Colomer D, Hoyos M, Sierra J, Esteve J, Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas
Blood. 2013 Apr 4. 2734-8. FI: 9.06
Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study.
Alvarez-Larrán A, Pereira A, Arellano-Rodrigo E, Hernández-Boluda JC, Cervantes F, Besses C
British journal of haematology. 2013 Jun. 865-71. FI: 4.942
Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma.
Sarasquete ME, Martínez-López J, Chillón MC, Alcoceba M, Corchete LA, Paiva B, Puig N, Sebastián E, Jiménez C, Mateos MV, Oriol A, Rosiñol L, Palomera L, Teruel AI, González Y, Lahuerta JJ, Bladé J, Gutiérrez NC, Fernández-Redondo E, González M, San Miguel JF, García-Sanz R
British journal of haematology. 2013 Oct. 223-34. FI: 4.942
Comments on the ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation.
Coordinadores:, Worner F, Cequier A, Grupo de Trabajo de la Sociedad Española de Cardiología para la guía de práctica clínica sobre el síndrome coronario agudo con elevación del segmento ST:, Bardají A, Bodí V, Bover R, Martínez-Sellés M, Sabaté M, Sionis A, Vázquez de Prada JA, Grupo de Revisores Expertos para la guía de síndrome coronario agudo con elevación del segmento ST:, Arós F, Arribas F, Barrabés J, Díaz de Castro O, Heras M, López Palop R, López-Sendón JL, Manito N, de Pablo MC, Ripoll T, San Román A, de la Torre JM, Comité de Guías de Práctica Clínica de la Sociedad Española de Cardiología:, Fernandez-Ortiz A, Alonso Gómez AM, Anguita M, Cequier A, Comín J, Diaz-Buschmann I, Fernández Lozano I, Gómez de Diego JJ, Pan M, Worner F
Revista española de cardiología. 2013 Jan. 41948. FI: 3.204
Nodular lesion on a woman's earlobe.
López V, Giner F
Actas dermo-sifiliográficas. 2013 Jun. 437-8
Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis.
Pajares B, Pollán M, Martín M, Mackey JR, Lluch A, Gavila J, Vogel C, Ruiz-Borrego M, Calvo L, Pienkowski T, Rodríguez-Lescure A, Seguí MA, Tredan O, Antón A, Ramos M, Cámara MD, Rodríguez-Martín C, Carrasco E, Alba E
Breast cancer research : BCR. 2013 Nov 6. R105
Images in clinical medicine. Myeloid sarcoma.
Montoro J, Tormo M
The New England journal of medicine. 2013 Dec 12. 2332. FI: 51.658
Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease.
Hoyos M, Nomdedeu JF, Esteve J, Duarte R, Ribera JM, Llorente A, Escoda L, Bueno J, Tormo M, Gallardo D, de Llano MP, Martí JM, Aventín A, Mangues R, Brunet S, Sierra J
European journal of haematology. 2013 Sep. 209-18. FI: 2.548
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H, PACE Investigators
The New England journal of medicine. 2013 Nov 7. 1783-96. FI: 51.658
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.
Abrisqueta P, Villamor N, Terol MJ, González-Barca E, González M, Ferrà C, Abella E, Delgado J, García-Marco JA, González Y, Carbonell F, Ferrer S, Monzó E, Jarque I, Muntañola A, Constants M, Escoda L, Calvo X, Bobillo S, Montoro JB, Montserrat E, Bosch F
Blood. 2013 Dec 5. 3951-9. FI: 9.06
Complications after lung transplantation in chronic obstructive pulmonary disease.
Cerón Navarro J, de Aguiar Quevedo K, Mancheño Franch N, Peñalver Cuesta JC, Vera Sempere FJ, Padilla Alarcón J
Medicina clínica. 2013 May 4. 385-9. FI: 1.399
A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera.
Hernández-Boluda JC, Pereira A, Cervantes F, Alvarez-Larrán A, Collado M, Such E, Arilla MJ, Boqué C, Xicoy B, Maffioli M, Bellosillo B, Marugán I, Amat P, Besses C, Guillem V
Bmc medical research methodology. 2012 May 31. 5221-8. FI: 9.06
Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera.
Alvarez-Larrán A, Pereira A, Cervantes F, Arellano-Rodrigo E, Hernández-Boluda JC, Ferrer-Marín F, Angona A, Gómez M, Muiña B, Guillén H, Teruel A, Bellosillo B, Burgaleta C, Vicente V, Besses C
Blood. 2012 Feb 9. 1363-9. FI: 9.06
Absence of mutations in the activation loop and juxtamembrane domains of VEGFR-1 and VEGFR-2 gene in chronic myelomonocytic leukemia (CMML).
Such E, Cervera J, Ibáñez M, Gómez-Seguí I, Luna I, López-Pavía M, Mallo M, Collado R, Vicente A, Hernández-Boluda JC, Luño E, Andreu R, Sanz GF, Sanz MA
Mechanisms of ageing and development. 2012 Mar. e50-1. FI: 2.764
A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia.
Valcárcel D, Montesinos P, Sánchez-Ortega I, Brunet S, Esteve J, Martínez-Cuadrón D, Ribera JM, Tormo M, Bueno J, Duarte R, Llorente A, Torres JP, Guardia R, Sanz MA, Sierra AJ, on behalf of the CETLAM Group
Cancer. 2012 Jan 15. 410-417. FI: 5.201
Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome.
Cordoba I, González-Porras JR, Nomdedeu B, Luño E, de Paz R, Such E, Tormo M, Vallespi T, Collado R, Xicoy B, Andreu R, Muñoz JA, Solé F, Cervera J, Del Cañizo C, On behalf of the Spanish Myelodysplastic Syndrome Registry
Cancer. 2012 Jan 1. 127-133. FI: 5.201
Donor CTLA-4 Genotype Influences Clinical Outcome after T Cell-Depleted Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Identical Sibling Donors.
Bosch-Vizcaya A, Pérez-García A, Brunet S, Solano C, Buño I, Guillem V, Martínez-Laperche C, Sanz G, Barrenetxea C, Martínez C, Tuset E, Lloveras N, Coll R, Guardia R, González Y, Roncero JM, Bustins A, Gardella S, Fernández C, Buch J, Gallardo D, GvHD/Immunotherapy committee of the Spanish Group for Hematopoietic Transplant (GETH)
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2012 Jan. 100-5. FI: 3.94
Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia.
Guillem V, Amat P, Cervantes F, Alvarez-Larrán A, Cervera J, Maffioli M, Bellosillo B, Collado M, Marugán I, Martínez-Ruiz F, Hernández-Boluda JC
Leukemia research. 2012 Feb. 174-81. FI: 2.764
Functional profile of cytomegalovirus (CMV)-specific CD8(+) T cells and kinetics of NKG2C(+) NK Cells associated with the resolution of CMV DNAemia in allogeneic stem cell transplant recipients.
Muñoz-Cobo B, Solano C, Benet I, Costa E, Remigia MJ, de la Cámara R, Nieto J, López J, Amat P, Garcia-Noblejas A, Bravo D, Clari MÁ, Navarro D
Journal of medical virology. 2012 Feb. 259-67. FI: 2.373
Performance of the QuantiFERON-cytomegalovirus (CMV) assay for detection and estimation of the magnitude and functionality of the CMV-specific gamma interferon-producing CD8(+) T-cell response in allogeneic stem cell transplant recipients.
Clari MÁ, Muñoz-Cobo B, Solano C, Benet I, Costa E, Remigia MJ, Bravo D, Amat P, Navarro D
Clinical and vaccine immunology : CVI. 2012 May. 791-6. FI: 2.598
Polymyositis after donor lymphocyte infusion.
Montoro J, Hernández-Boluda JC, Arbona C, Solano C
International journal of hematology. 2012 Sep. 386-9. FI: 1.681
Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the thyrosine kinase inhibitor era: comparison of two prospective parallel protocols.
Ribera JM, García O, Fernández-Abellán P, Lavilla E, Bernal MT, González-Campos J, Brunet S, Monteserín MC, Montesinos P, Sarrá J, Calbacho M, Alvarez-Larrán A, Tormo M, Oriol A
British journal of haematology. 2012 Nov. 485-8. FI: 4.942
Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival.
Santamaría C, Ramos F, Puig N, Barragán E, de Paz R, Pedro C, Insunza A, Tormo M, Del Cañizo C, Diez-Campelo M, Xicoy B, Salido E, Sánchez del Real J, Hernández M, Chillón C, Sanz GF, García-Sanz R, San Miguel JF, González M
Annals of hematology. 2012 Dec. 1887-95. FI: 2.866
Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen.
Sanz J, Boluda JC, Martín C, González M, Ferrá C, Serrano D, de Heredia CD, Barrenetxea C, Martinez AM, Solano C, Sanz MA, Sanz GF
Bone marrow transplantation. 2012 Oct. 1287-93. FI: 3.541
Liposomal cytarabine in central nervous system disease of haematological malignancies: more effective but more toxic?
Tormo Díaz M
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2012 Apr. 241-2. FI: 1.276

Role of the RUNX1/CBF-beta/p300/HIPK2 complex in the leukemic progression of the chronic myeloproliferative neoplasms.

Referencia:
PI13/00636
Investigador principal:
Juan Carlos Hernández Boluda
Entidad financiadora:
Instituto de Salud Carlos III
Duración:
01/01/2014 - 31/12/2016
Presupuesto total:
€79.860

Estudio de la predisposición genética individual a desarrollar leucemia aguda en los pacientes con síndromes mieloproliferativos crónicos Ph-negativos.

Referencia:
PS09/02324
Investigador principal:
Juan Carlos Hernández Boluda
Entidad financiadora:
Instituto de Salud Carlos III
Duración:
01/01/2010 - 31/12/2012
Presupuesto total:
€38.115